This study tests an experimental drug called TYRA300 in people with advanced bladder cancer or other solid tumors that have a specific change in the FGFR3 gene. The goal is to find the safest dose and see if the drug can shrink tumors. About 310 adults whose cancer has not respon…
Phase: PHASE1, PHASE2 • Sponsor: Tyra Biosciences, Inc • Aim: Disease control
Last updated May 17, 2026 00:50 UTC